Prescient Therapeutics Ltd
ASX:PTX

Watchlist Manager
Prescient Therapeutics Ltd Logo
Prescient Therapeutics Ltd
ASX:PTX
Watchlist
Price: 0.087 AUD -1.14% Market Closed
Market Cap: 91.5m AUD

Net Margin
Prescient Therapeutics Ltd

-3 245.8%
Current
-3 325%
Average
-6.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-3 245.8%
=
Net Income
-7.3m
/
Revenue
225.6k

Net Margin Across Competitors

No Stocks Found

Prescient Therapeutics Ltd
Glance View

Market Cap
91.5m AUD
Industry
Biotechnology

Prescient Therapeutics Ltd. is a biopharmaceutical company. The company is headquartered in South Melbourne, Victoria. The firm is focused on developing therapies for a range of cancers, using CAR-T and targeted therapy approaches. The firm has a broad pipeline of cancer treatments, comprising CAR-T and targeted therapies, for a range of different cancers. Its Phase 1b clinical candidate PTX-100 is a drug that blocks the cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). PTX-200, a Phase 1b/2a clinical candidate is a PH domain inhibitor that inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Its OmniCAR, is an immune receptor platform enabling controllable T-cell activity and multi- antigen targeting with a single cell product is for the treatment of Acute Myeloid Leukemia (AML), Her2+ solid tumors, including breast, ovarian and gastric cancers and glioblastoma multiforme (GBM).

PTX Intrinsic Value
0.002 AUD
Overvaluation 97%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-3 245.8%
=
Net Income
-7.3m
/
Revenue
225.6k
What is the Net Margin of Prescient Therapeutics Ltd?

Based on Prescient Therapeutics Ltd's most recent financial statements, the company has Net Margin of -3 245.8%.

Back to Top